Press Releases Press Releases Year: - Any -2019201820172016201520142013 December 19, 2018 Summary ToggleMelinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million November 27, 2018 Summary ToggleMelinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam) November 07, 2018 Summary ToggleMelinta Therapeutics Reports Third Quarter 2018 Financial Results October 31, 2018 Summary ToggleMelinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors October 29, 2018 Summary ToggleMelinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP October 26, 2018 Summary ToggleMelinta Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018 October 22, 2018 Summary ToggleMelinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer October 05, 2018 Summary ToggleMelinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program October 02, 2018 Summary ToggleMelinta Therapeutics Publishes Complete Results from Phase III TANGO 2 Study of Vabomere™ (meropenem and vaborbactam) October 01, 2018 Summary ToggleMelinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
Press Releases Year: - Any -2019201820172016201520142013 December 19, 2018 Summary ToggleMelinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million November 27, 2018 Summary ToggleMelinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam) November 07, 2018 Summary ToggleMelinta Therapeutics Reports Third Quarter 2018 Financial Results October 31, 2018 Summary ToggleMelinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors October 29, 2018 Summary ToggleMelinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP October 26, 2018 Summary ToggleMelinta Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018 October 22, 2018 Summary ToggleMelinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer October 05, 2018 Summary ToggleMelinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program October 02, 2018 Summary ToggleMelinta Therapeutics Publishes Complete Results from Phase III TANGO 2 Study of Vabomere™ (meropenem and vaborbactam) October 01, 2018 Summary ToggleMelinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
